Alendronate Sodium
FDA Approved, EMA Approved
Description
Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption and increases bone mineral density. It is used in the treatment of osteoporosis and has been utilized off-label in managing avascular necrosis to prevent further bone collapse. The drug binds to hydroxyapatite in bone and reduces bone turnover.
Indications & Therapeutic Use
osteoporosis, Paget's disease of bone, idiopathic avascular necrosis (off-label)
Linked Diseases:
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Alendronate Sodium
| Generic Name | Alendronate Sodium |
| Brands | 1 brand available |
| Active Ingredient | Alendronate Sodium |
| Drug Class | osteoporosis |
| Manufacturer | Merck & Co. |
| Dosage Forms | Oral tablet, 5mg, 10mg, 35mg, 70mg |
| Medical Code | M05BA04 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes